Correction to “Protecting infants against RSV disease: an impact and cost-effectiveness comparison of long-acting monoclonal antibodies and maternal vaccination” [The Lancet Regional Health – Europe 38 (2024) 100829] (The Lancet Regional Health - Europe (2024) 38, (S266677622300248X), (10.1016/j.lanepe.2023.100829))

David Hodgson, Neil Wilkins, Edwin van Leeuwen, Conall H. Watson, Jonathan Crofts, Stefan Flasche, Mark Jit, Katherine E. Atkins

Research output: Contribution to journalComment/debatepeer-review

Abstract

The authors have noticed an error in the Supplementary Material Table S1, in which the code erroneously calculated the average instead of the sum across the age groups, resulting in the Supplementary Table S1 displaying the mean number of cases rather than the total. This aggregated data was subsequently used to plot Supplementary Figure S2. The code has now been corrected to sum the outputs, as reflected in the revised Supplementary Table S1 and Supplementary Figure S2, which can be found below: Since this error is confined solely to the aggregated values presented in that Table and Figure, it does not affect any interpretations and conclusions in the article. If you have any further questions or comments, we will of course be happy to address them. The authors would like to apologise for any inconvenience caused.

Original languageEnglish (US)
Article number101073
JournalThe Lancet Regional Health - Europe
Volume45
DOIs
StatePublished - Oct 2024

ASJC Scopus subject areas

  • Internal Medicine
  • Oncology
  • Health Policy

Fingerprint

Dive into the research topics of 'Correction to “Protecting infants against RSV disease: an impact and cost-effectiveness comparison of long-acting monoclonal antibodies and maternal vaccination” [The Lancet Regional Health – Europe 38 (2024) 100829] (The Lancet Regional Health - Europe (2024) 38, (S266677622300248X), (10.1016/j.lanepe.2023.100829))'. Together they form a unique fingerprint.

Cite this